PULM News and Press, Pulmatrix Inc.

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...

2024-05-17 16:30:05 ET More on Pulmatrix Financial information for Pulmatrix Read the full article on Seeking Alpha For further details see: Pulmatrix files for $95M mixed shelf

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...

2024-05-10 13:53:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pulmatrix (NASDAQ: PULM ) just reported results for the first quarter of 2024. Pulmatrix reported earnings per share of 23 cents. The company reported revenue of $5.89...

2024-05-10 08:08:30 ET More on Pulmatrix Financial information for Pulmatrix Read the full article on Seeking Alpha For further details see: Pulmatrix GAAP EPS of $0.23, revenue of $5.89M

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire $16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results ...

Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...

2024-03-28 14:50:41 ET More on Pulmatrix Seeking Alpha’s Quant Rating on Pulmatrix Financial information for Pulmatrix Read the full article on Seeking Alpha For further details see: Pulmatrix GAAP EPS of -$3.87, revenue of $7.3M

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update PR Newswire 2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3 rd amendment to Cipla partnership resulted in the wind down o...

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives PR Newswire Cipla to take sole responsibility for development of PUR1900, refocu...